Sep 20, 2022 / 01:00PM GMT
Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst
Great. Thanks, everyone, for joining. I'm Robbie Marcus, the medical device analyst at JPMorgan. Very happy to have Bryan Hanson, the CEO of Zimmer Biomet. And in the audience, he won't be on stage but Keri Mattox of -- in Investor Relations. So I appreciate you making the trip out here. Thanks for joining.
Bryan C. Hanson - Zimmer Biomet Holdings, Inc. - Chairman, President & CEO
Yes. It looks like a long time since we've been in person. You seem much taller than I remember.
Questions and Answers:
Robert Justin Marcus - JPMorgan Chase & Co, Research Division - AnalystI appreciate that. Well, good. So I wanted to start off high level. Medtech has had a difficult few years. COVID has really disrupted the normal flow back and forth. And here we are, back in person, back across the [PON] meeting, and it feels -- nobody is wearing masks. Joe Biden just said, it's no longer a pandemic anymore. And I think we're starting to see,